Anixa Biosciences Management
Management criteria checks 2/4
Anixa Biosciences' CEO is Amit Kumar, appointed in Jul 2017, has a tenure of 7.5 years. total yearly compensation is $3.64M, comprised of 19.8% salary and 80.2% bonuses, including company stock and options. directly owns 1.61% of the company’s shares, worth $1.20M. The average tenure of the management team and the board of directors is 7.8 years and 6.3 years respectively.
Key information
Amit Kumar
Chief executive officer
US$3.6m
Total compensation
| CEO salary percentage | 19.8% |
| CEO tenure | 7.5yrs |
| CEO ownership | 1.6% |
| Management average tenure | 7.8yrs |
| Board average tenure | 6.3yrs |
Recent management updates
Recent updates
Are Investors Undervaluing Anixa Biosciences, Inc. (NASDAQ:ANIX) By 40%?
Dec 19
We're Not Very Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Rate
Sep 12We're Hopeful That Anixa Biosciences (NASDAQ:ANIX) Will Use Its Cash Wisely
May 23We're Not Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn
Jan 19We Think Anixa Biosciences (NASDAQ:ANIX) Can Easily Afford To Drive Business Growth
Oct 06Is There An Opportunity With Anixa Biosciences, Inc.'s (NASDAQ:ANIX) 41% Undervaluation?
Apr 27Are Investors Undervaluing Anixa Biosciences, Inc. (NASDAQ:ANIX) By 36%?
Jan 13We're Interested To See How Anixa Biosciences (NASDAQ:ANIX) Uses Its Cash Hoard To Grow
Sep 26Anixa adds 11% after dosing initiation in CAR-T ovarian cancer trial
Aug 15Anixa to get additional US patent linked to breast cancer vaccine technology
Jul 21Anixa Biosciences (NASDAQ:ANIX) Is In A Good Position To Deliver On Growth Plans
Jun 13Anixa: Making Sense Of A Bullish Move Up In Bearish Biotech Times
May 11We're Interested To See How Anixa Biosciences (NASDAQ:ANIX) Uses Its Cash Hoard To Grow
Feb 24Companies Like Anixa Biosciences (NASDAQ:ANIX) Can Afford To Invest In Growth
Oct 28Our First Look At Anixa Biosciences
Sep 23Here's Why We're Not At All Concerned With Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Situation
Jun 12OntoChem assigns Anixa covid-19 drug discovery project to MolGenie
May 07Anixa Biosciences (NASDAQ:ANIX) Is In A Good Position To Deliver On Growth Plans
Jan 13
Anixa Biosciences, Cleveland Clinic in ovarian cancer vaccine pact
Dec 01CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jul 31 2024 | n/a | n/a | -US$12m |
| Apr 30 2024 | n/a | n/a | -US$12m |
| Jan 31 2024 | n/a | n/a | -US$11m |
| Oct 31 2023 | US$4m | US$720k | -US$10m |
| Jul 31 2023 | n/a | n/a | -US$11m |
| Apr 30 2023 | n/a | n/a | -US$11m |
| Jan 31 2023 | n/a | n/a | -US$12m |
| Oct 31 2022 | US$2m | US$631k | -US$14m |
| Jul 31 2022 | n/a | n/a | -US$14m |
| Apr 30 2022 | n/a | n/a | -US$16m |
| Jan 31 2022 | n/a | n/a | -US$15m |
| Oct 31 2021 | US$11m | US$573k | -US$13m |
| Jul 31 2021 | n/a | n/a | -US$11m |
| Apr 30 2021 | n/a | n/a | -US$9m |
| Jan 31 2021 | n/a | n/a | -US$10m |
| Oct 31 2020 | US$2m | US$522k | -US$10m |
| Jul 31 2020 | n/a | n/a | -US$10m |
| Apr 30 2020 | n/a | n/a | -US$9m |
| Jan 31 2020 | n/a | n/a | -US$9m |
| Oct 31 2019 | US$665k | US$476k | -US$12m |
| Jul 31 2019 | n/a | n/a | -US$15m |
| Apr 30 2019 | n/a | n/a | -US$18m |
| Jan 31 2019 | n/a | n/a | -US$17m |
| Oct 31 2018 | US$12m | US$425k | -US$14m |
Compensation vs Market: Amit's total compensation ($USD3.64M) is above average for companies of similar size in the US market ($USD649.25K).
Compensation vs Earnings: Amit's compensation has increased whilst the company is unprofitable.
CEO
Amit Kumar (60 yo)
7.5yrs
Tenure
US$3,639,651
Compensation
Dr. Amit Kumar, Ph.D. was a Director at Ascent Solar Technologies, Inc. since June 2007 until September 16, 2022 and had been its Independent Chairman of the Board since January 2011 until September 16, 20...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, Chairman & Co-Chair of CBAB | 7.5yrs | US$3.64m | 1.61% $ 1.2m | |
| President | 8.2yrs | US$1.97m | 0.11% $ 81.7k | |
| Senior Vice President of Engineering | 12.3yrs | US$275.00k | no data | |
| Chief Development Officer & Chair Breast Cancer Clinical Advisory Board | 3.3yrs | no data | no data |
7.8yrs
Average Tenure
64.5yo
Average Age
Experienced Management: ANIX's management team is seasoned and experienced (7.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, Chairman & Co-Chair of CBAB | 12.2yrs | US$3.64m | 1.61% $ 1.2m | |
| Chief Development Officer & Chair Breast Cancer Clinical Advisory Board | 1.9yrs | no data | no data | |
| Lead Independent Director | 7.5yrs | US$169.35k | 2.84% $ 2.1m | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | 6.3yrs | no data | no data | |
| Member of Scientific Advisory Board | 5.3yrs | no data | no data | |
| Member of Breast Cancer Clinical Advisory Board | 1.9yrs | no data | no data | |
| Member of SAB & Breast Cancer Clinical Advisory Board | 6.3yrs | US$169.35k | 0.36% $ 266.8k | |
| Member of Scientific Advisory Board | 6.3yrs | no data | no data | |
| Member of Scientific Advisory Board | 6.3yrs | no data | no data | |
| Member of Scientific Advisory Board | 6.3yrs | no data | no data | |
| Independent Director | 5.3yrs | US$169.35k | 0.14% $ 105.9k |
6.3yrs
Average Tenure
70yo
Average Age
Experienced Board: ANIX's board of directors are considered experienced (6.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/02 06:08 |
| End of Day Share Price | 2025/01/02 00:00 |
| Earnings | 2024/07/31 |
| Annual Earnings | 2023/10/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Anixa Biosciences, Inc. is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Andrew D'Silva | B. Riley Securities, Inc. |
| Jason Kolbert | D. Boral Capital LLC. |
| Yi Chen | H.C. Wainwright & Co. |